Current challenges in the management of invasive fungal infections
Journal
Journal of Infection and Chemotherapy
Journal Volume
14
Journal Issue
2
Pages
77-85
Date Issued
2008
Author(s)
Abstract
The incidence of invasive fungal infections (IFIs) has increased over the past two decades, as the populations of patients at risk have continued to rise. Early and accurate diagnosis and the subsequent usage of appropriate antifungal therapy are difficult, which leads to a high mortality rate in patients with IFI. Along with the widespread use of antifungal prophylaxis, the epidemiology of invasive fungal pathogens has changed. Non-albicans Candida, Non-fumigatus Aspergillus, and molds other than Aspergillus have become more common pathogens causing invasive diseases, and most of these emerging fungi are resistant to or less susceptible than others to standard antifungal agents. Therefore, invasive infections due to these previously rare fungi are more difficult to treat. Advances in more potent and less toxic antifungal agents, such as second-generation triazoles and echinocandins, may potentially improve the outcomes of these infections. Recent advances in detecting fungal cell-wall components and genomic DNA also allow earlier diagnosis. This article reviews the changing spectrum of invasive fungal infections and the introduction of recent advances in diagnostic tools and antifungal agents. ? 2008 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
SDGs
Other Subjects
amphotericin; amphotericin B; amphotericin B deoxycholate; amphotericin B lipid complex; anidulafungin; antifungal agent; antineoplastic agent; caspofungin; echinocandin; fluconazole; fungal DNA; galactomannan; genomic DNA; glucan; itraconazole; micafungin; posaconazole; ravuconazole; steroid; triazole derivative; voriconazole; Absidia; antibiotic prophylaxis; antibiotic resistance; antibiotic sensitivity; antifungal activity; aspergillosis; Aspergillus; Aspergillus flavus; Aspergillus fumigatus; Aspergillus niger; Aspergillus terreus; Candida; Candida albicans; Candida glabrata; Candida guilliermondii; Candida krusei; Candida lusitaniae; Candida parapsilosis; Candida rugosa; Candida tropicalis; candidemia; candidiasis; cell wall; clinical trial; combination chemotherapy; Cunninghamella; diagnostic accuracy; diagnostic test; DNA determination; drug dose reduction; drug efficacy; drug mechanism; drug metabolism; drug potency; drug safety; early diagnosis; esophagus candidiasis; febrile neutropenia; food; food drug interaction; fungal cell; fungemia; fungicidal activity; Fusarium; hematologic malignancy; hematopoietic stem cell transplantation; hospital infection; human; immune deficiency; immunosuppressive treatment; incidence; infection risk; kidney failure; laboratory diagnosis; lipid diet; liver failure; loading drug dose; maintenance drug dose; monotherapy; mortality; mucormycosis; mycosis; nonhuman; polymerase chain reaction; review; Rhizomucor; Rhizopus; treatment outcome
Type
review